Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Gilead Sciences
Gilead Sciences
FDA requires 'boxed warning' for CAR-T cancer therapies
Reuters
Mon, 01/22/24 - 10:10 pm
CAR-T
FDA
warnings
Gilead Sciences
JNJ
Novartis
Gilead's Trodelvy fails to extend survival in lung cancer study, prompting selloff
Fierce Pharma
Mon, 01/22/24 - 11:21 am
Gilead Sciences
antibody-drug conjugate
Trodelvy
lung cancer
clinical trials
Gilead calls off Oceanside manufacturing expansion, uproots biologics development team
Fierce Pharma
Wed, 01/17/24 - 08:45 pm
Gilead Sciences
biologics
California
drug manufacturing
CAR-T hype faces infrastructure reality check
Fierce Pharma
Tue, 01/16/24 - 09:22 am
CAR-T
cell therapy
gene therapy
Gilead Sciences
JNJ
Gilead Sciences Must Face Consumer Claims Over Older, Lower-Quality Drugs, Court Rules
BioSpace
Fri, 01/12/24 - 11:34 am
Gilead Sciences
legal
HUV
10 clinical trials to watch in the first half of 2024
BioPharma Dive
Wed, 01/3/24 - 05:08 pm
clinical trials
Beam Therapeutics
Moderna Therapeutics
Pfizer
Sanofi
Gilead Sciences
JNJ
Amylx
Roche
Alnylam Pharmaceuticals
Vertex Pharmaceuticals
Gilead downloads solid tumor program from Compugen for $60M upfront
Fierce Biotech
Tue, 12/19/23 - 10:05 am
Gilead Sciences
CompuGen
solid tumors
Gilead cuts 7% of staff at Kite Pharma unit as 'refreshed business strategy' introduced
Fierce Pharma
Wed, 11/29/23 - 11:55 am
Kite Pharma
Gilead Sciences
layoffs
Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash
BioSpace
Wed, 11/15/23 - 11:11 am
Gilead Sciences
Kite Pharma
Arcellx
CART-ddBCMA
lymphoma
Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat
Investors Business Daily
Wed, 11/8/23 - 11:39 am
Gilead Sciences
earnings
Veklury
Gilead Sciences and Arcus Biosciences report cancer trial data
Clinical Trials Arena
Tue, 11/7/23 - 09:46 am
Gilead Sciences
Arcus Biosciences
domvanalimab
zimberelimab
upper GI cancers
clinical trials
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Fierce Biotech
Mon, 10/30/23 - 11:58 am
Merck KGaA
PARP inhibitors
Lynparza
Zejula
AstraZeneca
Gilead Sciences
solid tumors
Gilead plans European trial of twice-yearly HIV PrEP drug
Pharmaphorum
Wed, 10/18/23 - 10:08 am
Gilead Sciences
clinical trials
HIV
PrEP
Sunlenca
Europe
Gilead pays $100M for first dibs on all Assembly Bio assets, bolting antiviral engine to its R&D group
Fierce Biotech
Tue, 10/17/23 - 10:27 am
Gilead Sciences
Assembly Biosciences
antivirals
hepatitis B
Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data
BioSpace
Wed, 09/27/23 - 11:12 pm
Gilead Sciences
magrolimab
clinical trials
blood cancers
Gilead Sciences, after trial win, moves ahead with $247M settlement in HIV antitrust case
Fierce Pharma
Tue, 09/26/23 - 11:47 am
Gilead Sciences
Teva Pharmaceutical
HIV
legal
antitrust
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
Clinical Trials Arena
Fri, 09/22/23 - 12:00 pm
Gilead Sciences
Trodelvy
TROP-2
non-small cell lung cancer
Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Clinical Trials Arena
Mon, 09/18/23 - 09:53 am
Gilead Sciences
Kite Pharma
Yescarta
clinical trials
CAR-T
relapsed or refractory large B-cell lymphoma
Gilead unveils promising data from trial of combo therapy for lung cancer
Clinical Trials Arena
Mon, 09/11/23 - 12:34 pm
Gilead Sciences
Trodelvy
metastatic non-small cell lung cancer
Gilead-backed study warns IRA price negotiations could hit R&D harder than expected
Fierce Biotech
Wed, 09/6/23 - 11:40 am
Gilead Sciences
Inflation Reduction Act
R&D
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »